Physicians and teaching hospitals can begin reviewing the Sunshine Act data attributed to them by applicable manufacturers on Monday, April 6.
The 2014 data – the first full year of reported data – was due on March 31. Physicians and
Sunshine Act data submission / correction begins today
Starting today, applicable manufacturers and GPOs can begin submitting data about Sunshine Act payments and transfers of value for the 2014 calendar year, according to a listserv email from CMS. Applicable manufacturers and GPOs can also submit corrected 2013 data,
Preventing pharmaceutical fraud: what’s on the horizon for Australia?
The possible introduction of a United States-type False Claims Act (FCA) in Australia will see a sharp increase in allegations of fraudulent conduct in many industries, particularly for those in the pharmaceutical industry.
The cost of fraud to
Top things you should know about the Sunshine Act database
The shifting guidance on whether the industry should report mere funding of educational events, the likely enforcement ahead by federal and state agencies, and maps showing the “hotspots” of consulting, food and beverage, and travel and lodging payments: here’s what
Ranbaxy Pharmaceuticals to pay US$39.75m to resolve Texas Medicaid fraud enforcement action
On October 16, the Texas Office of Attorney General settled an enforcement action against Ranbaxy, an Indian manufacturer of generic drugs.
The settlement resolves the State’s lawsuit under the Texas Medicaid Fraud Prevention Act (“TMFPA”) against Ranbaxy for allegedly reporting
Third Circuit tightens up FCA original source rule
A decision from the Third Circuit this week makes it harder for whistleblowers to qualify as an “original source” under the False Claims Act (FCA).
The Third Circuit ruled in United States et al. v. AstraZeneca Pharmaceuticals LP that whistleblowers
Sunshine around the world
In the United States, the healthcare industry is familiar with the Sunshine Act’s tracking and reporting requirements related to payments and transfers of value to physicians, as well as to physician ownership and investment interests.
And around the world, new
Sunshine Act data now available
The “Open Payments” database of transactions reported under the Physician Payments Sunshine Act has launched on its scheduled release date of September 30 and is now available for public review.
Pharmaceutical and medical-device manufacturers reported information about their financial relationships
Drugmakers liable for improper copay coupon use
Pharmaceutical manufacturers have primary responsibility for ensuring that Medicare Part D members do not redeem copay coupons that could trigger federal inducement prohibitions, according to a report and Special Advisory Bulletin released on September 19 by the Office of Inspector
Sunshine data 33 percent unpublishable, penalties next?
Despite extending the dispute-and-resolution deadline to account for the days that the Centers for Medicare & Medicaid Services (CMS) pulled down the reporting system, the public Physician Payments Sunshine Act website is still expected to go live in a matter